Lanreotide Acetate Powder
NDC Package 83589-143-08

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Lanreotide Acetate powders is a medication a long-acting form of lanreotide. This formulation utilizes a powder delivery system. Marketed by Nanjing Chengong Pharmaceutical Co., Ltd., this product is identified by NDC 83589-143.

Identification & Billing

NDC Package Code
83589-143-08
Package Description
100 g in 1 BOTTLE
Product Code
83589-143
11-Digit Billing Format
83589014308

Clinical Specifications

Proprietary Name
Lanreotide Acetate
Non-Proprietary Name
Lanreotide Acetate
Substance Name
Lanreotide Acetate
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
LANREOTIDE ACETATE 1 g/g
Usage Information
This medication is a long-acting form of lanreotide. Lanreotide is used to treat a condition called acromegaly that occurs when the body makes too much of a certain natural substance called growth hormone. It is used when surgery or radiation treatment have not been fully successful or cannot be used. Treating acromegaly helps reduce the risk of serious problems such as diabetes and heart disease. Lanreotide works by decreasing the amount of growth hormone to normal levels. This drug is not a cure for acromegaly. It is used for the long-term treatment of this condition. This medication is also used to treat certain cancer or tumors of the stomach, intestines, or pancreas. It may help to slow down the growth of these tumors. Lanreotide is also used to treat carcinoid syndrome. It may help reduce the need to use another medication to treat diarrhea or flushing caused by carcinoid syndrome.

Regulatory & Marketing

Labeler Name
Nanjing Chengong Pharmaceutical Co., Ltd.
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
02-25-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (83589-143). Click a package code to view its specific billing and regulatory data.

83589-143-01
1 g in 1 VIAL
83589-143-02
1 g in 1 BOTTLE
83589-143-03
5 g in 1 VIAL
83589-143-04
5 g in 1 BOTTLE
83589-143-05
10 g in 1 BOTTLE
83589-143-06
50 g in 1 BOTTLE
83589-143-07
50 g in 1 BAG
83589-143-09
100 g in 1 BAG
83589-143-10
250 g in 1 BAG
83589-143-11
500 g in 1 BAG

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83589-143-08 identifies a specific commercial package of 100 g in 1 bottle of Lanreotide Acetate (UNFINISHED drug), a bulk ingredient labeled by Nanjing Chengong Pharmaceutical Co., Ltd.. This powder is formulated for use and contains lanreotide acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nanjing Chengong Pharmaceutical Co., Ltd. on February 25, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is a long-acting form of lanreotide. Lanreotide is used to treat a condition called acromegaly that occurs when the body makes too much of a certain natural substance called growth hormone. It is used when surgery or radiation treatment have not been fully successful or cannot be used. Treating acromegaly helps reduce the risk of serious problems such as diabetes and heart disease. Lanreotide works by decreasing the amount of growth hormone to normal levels. This drug is not a cure for acromegaly. It is used for the long-term treatment of this condition. This medication is also used to treat certain cancer or tumors of the stomach, intestines, or pancreas. It may help to slow down the growth of these tumors. Lanreotide is also used to treat carcinoid syndrome. It may help reduce the need to use another medication to treat diarrhea or flushing caused by carcinoid syndrome.

How is this Nanjing Chengong Pharmaceutical Co., Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83589014308. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83589-143-08
11-Digit CMS (5-4-2)
83589-0143-08

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.